Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-05-31-Speech-3-168"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20060531.16.3-168"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
Madam President, I should first of all like to compliment and congratulate Mrs Grossetête. It is an important topic we are discussing this evening. Children take medicinal products; lots of them, relatively speaking. That is why it is so important that children are administered the right medicinal products, in the right dose and in the right form of administration. The Commission’s proposal is of major significance to children, parents and industry alike. That is why I find it so regrettable that today, Mrs Roth-Behrendt is unable to be present, for she went all-out for this legislation, and I would like to take this opportunity to wish her a speedy recovery.
I have to say that our group was very divided on this proposal. Of course, everyone is agreed that medicinal products for paediatric use must be developed and that their manufacturers must be given reasonable compensation for research they carry out into them. This compensation could even be substantial, but for many of our group, the extension of the patent by another six months went a little too far.
Enquiries I made at a renowned enterprise revealed that, in most cases, research into the use of medicinal products for paediatric use costs no less than EUR 8 million. When patents are extended by six months, profits increase into a multiple of this sum, namely to some EUR 200 to 300 million, which are hefty profits. Blockbusters command even higher amounts. It is, of course, also possible that the profits are a little lower in the case of medicinal products for rare diseases. That is why we have argued in favour of proportionality. We think that the reward should be in proportion to the costs incurred. That is a very simple and normal principle.
The bill for medicinal products need not become unnecessarily steep and that is why – and that is also my final comment – we are looking forward with eager anticipation to the assessment and review of this directive, which will then make evident what the six months’ of patent extension have yielded, what the economic costs are and whether it causes detriment to the industry’s innovative strength."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples